$2 Billion Stock Buyback Authorized by United Therapeutics, $1.5 Billion ASR Launched
Summary
United Therapeutics Corporation announced a new $2 billion stock repurchase authorization and immediately entered into a $1.5 billion accelerated share repurchase (ASR) program. This significant capital allocation follows recent positive developments, including robust 2025 financial results reported on February 25th and highly positive Phase 3 study results for ralinepag on March 2nd. The $2 billion authorization represents a material commitment to returning capital to shareholders, signaling management's confidence in the company's financial strength and future prospects. The immediate $1.5 billion ASR is expected to quickly reduce the outstanding share count, which is typically accretive to earnings per share and supportive of the stock price. Traders will be watching the execution of this program and its impact on UTHR's valuation.
At the time of this announcement, UTHR was trading at $478.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21B. The 52-week trading range was $266.98 to $537.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.